India
· Delayed Price · Currency is INR Alembic Pharmaceuticals Statistics
Total Valuation
Alembic Pharmaceuticals has a market cap or net worth of INR 234.07 billion. The enterprise value is 238.00 billion.
| Market Cap | 234.07B |
| Enterprise Value | 238.00B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Jul 15, 2024 |
Share Statistics
Alembic Pharmaceuticals has 196.56 million shares outstanding. The number of shares has increased by 0.10% in one year.
| Shares Outstanding | 196.56M |
| Shares Change (YoY) | +0.10% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | 15.65% |
| Float | 58.27M |
Valuation Ratios
The trailing PE ratio is 37.18 and the forward PE ratio is 31.62. Alembic Pharmaceuticals's PEG ratio is 1.51.
| PE Ratio | 37.18 |
| Forward PE | 31.62 |
| PS Ratio | 3.72 |
| PB Ratio | 4.86 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.51 |
Enterprise Valuation
| EV / Earnings | 37.78 |
| EV / Sales | 3.78 |
| EV / EBITDA | 24.62 |
| EV / EBIT | 34.22 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.53 |
| Debt / FCF | n/a |
| Interest Coverage | 12.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 8.35% |
| Revenue Per Employee | 4.24M |
| Profits Per Employee | 423,967 |
| Employee Count | 14,858 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +60.29% |
| 50-Day Moving Average | 1,155.47 |
| 200-Day Moving Average | 1,014.25 |
| Relative Strength Index (RSI) | 50.93 |
| Average Volume (20 Days) | 281,110 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alembic Pharmaceuticals had revenue of INR 63.04 billion and earned 6.30 billion in profits. Earnings per share was 32.03.
| Revenue | 63.04B |
| Gross Profit | 45.27B |
| Operating Income | 6.96B |
| Pretax Income | 6.59B |
| Net Income | 6.30B |
| EBITDA | 9.48B |
| EBIT | 6.96B |
| Earnings Per Share (EPS) | 32.03 |
Balance Sheet
The company has 1.20 billion in cash and 5.13 billion in debt, giving a net cash position of -3.93 billion or -19.99 per share.
| Cash & Cash Equivalents | 1.20B |
| Total Debt | 5.13B |
| Net Cash | -3.93B |
| Net Cash Per Share | -19.99 |
| Equity (Book Value) | 48.18B |
| Book Value Per Share | 245.12 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 71.82%, with operating and profit margins of 11.04% and 9.99%.
| Gross Margin | 71.82% |
| Operating Margin | 11.04% |
| Pretax Margin | 10.45% |
| Profit Margin | 9.99% |
| EBITDA Margin | 15.04% |
| EBIT Margin | 11.04% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 11.00 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | 37.50% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.10% |
| Shareholder Yield | 0.80% |
| Earnings Yield | 2.69% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |